@Semaglutide Tag

09 Nov

Posted at 12:37h in Weight Research

Prescription Medication Notice: Semaglutide and tirzepatide are prescription medications and should only be prescribed and monitored by your healthcare provider. Do not stop, restart or change your dose without medical advice. Buy medicines only from licensed pharmacies with a valid local prescription, and check the rules for carrying or importing prescription medicines before you travel. These medicines are not used during pregnancy and are not suitable for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Seek urgent care for severe or persistent abdominal pain, signs of dehydration, or swelling of the face, lips or throat.

MedicalResearch.com Interview with: Dr. Pedro Yelamo Vera, MD General Practitioner, licensed in Spain (Official College of Physicians of Bizkaia) Dr. Yelamo runs an independent telemedicine practice for English- and Spanish-speaking patients.

Editorial Notice: This interview is general information and is not specific medical advice. Dr. Yelamo runs a private telemedicine practice, disclosed below. Providers named or linked in this article are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.

08 Nov

Posted at 11:48h in Telemedicine, Weight Research

Prescription Medication Notice: Semaglutide and tirzepatide are prescription medications and should only be prescribed and monitored by your healthcare provider. Do not use them if you or a family member has had medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, or if you are pregnant or planning pregnancy. Tell your provider about all medications you take, especially insulin or a sulfonylurea. Seek prompt medical care for severe or persistent abdominal pain, which can be a sign of pancreatitis, for pain in the upper right abdomen or yellowing of the skin, or for severe vomiting or diarrhea that leaves you unable to keep fluids down. Compounded versions are not FDA-approved.

Editorial Notice: This article is general information and is not specific medical advice. Programs and providers named or linked in this article are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.

GLP-1 medications have changed how doctors treat obesity in only a few years. Semaglutide and tirzepatide now produce weight loss in clinical trials that approaches what was once seen mainly with surgery, and demand has grown well beyond what most primary care offices can handle.

Wherever a patient starts, it helps to understand what the research supports, where the limits are, and which questions to raise before the first dose.

30 Sep

Posted at 11:54h in Weight Research

Key Takeaways

  • GLP-1 medications can support weight management, but they are prescription treatments rather than stand-alone solutions or quick fixes.
  • A responsible program screens for medical risks, reviews other medications, explains realistic expectations, and provides follow-up after treatment begins.
  • Product source matters. FDA-approved drugs and compounded versions do not go through the same review process.
  • Nutrition, physical activity, sleep, and a long-term maintenance plan remain important even when medication is appropriate.

Interest in GLP-1 medications has changed the conversation about obesity treatment. For many adults, these medications can reduce appetite and support clinically meaningful weight loss when combined with lifestyle intervention. They have also created a crowded online market in which polished advertising can make very different care models look similar.

[caption id="attachment_76379" align="aligncenter" width="500"]Photo by Haberdoedas Photography: https://www.pexels.com/photo/close-up-of-semaglutide-injection-pen-on-surface-32532049/ Photo by Haberdoedas[/caption]

The key question is therefore not simply whether a program offers semaglutide or another GLP-1 medication. Patients should also ask how the program determines candidacy, where prescriptions are filled, how side effects are monitored, and what happens when treatment goals or circumstances change.

22 Jun

Posted at 20:36h in Author Interviews, Endocrinology, Orthopedics, Weight Research

Semaglutide Linked to Fewer Bone Fractures Despite Greater Weight Loss in Type 2 Diabetes

[caption id="attachment_74422" align="alignleft" width="200"]Jairo Norena Velasquez, Dr. Norena Velasquez[/caption] MedicalResearch.com Interview with: Jairo Norena Velasquez, MD Associate Division Chief, Endocrinology Division Alameda Health System Oakland, California
MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Type 2 diabetes is associated with a paradoxically elevated fracture risk — up to three times higher than the general population — despite normal or even elevated bone mineral density. The underlying problem is poor bone quality driven by chronic hyperglycemia, advanced glycation end-product accumulation, and increased cortical porosity. Compounding this, intentional weight loss — a cornerstone of diabetes treatment — can accelerate bone loss by reducing mechanical loading on the skeleton.

Semaglutide is one of the most effective weight-loss agents available, yet direct real-world comparisons of its skeletal effects against other active weight-loss therapies were lacking.

Using the Atropos Health Eos EHR database — 161 million US patients from 2016 to 2023 — we compared fracture incidence and BMI change in adults with type 2 diabetes initiating semaglutide versus dulaglutide, phentermine/topiramate, or bupropion/naltrexone, using high-dimensional propensity score matching (17,506 pairs per group).

Semaglutide was associated with greater weight loss (mean delta BMI −1.9 vs. −1.2 kg/m²; difference −0.72 kg/m², p < 0.001) and a 15% reduction in fracture incidence (HR 0.85, 95% CI 0.77–0.93; p < 0.001) over a mean follow-up of 3.6 years.

11 Jun

Posted at 14:13h in Supplements, Weight Research
Berberine in the Age of Ozempic

Supplement Notice: Berberine is a dietary supplement and is not approved by the U.S. Food and Drug Administration to diagnose, treat, cure, or prevent any disease. It is not a substitute for prescription medications including metformin, semaglutide (Ozempic/Wegovy), or any other FDA-approved therapy. Berberine can interact with prescription medications including warfarin, cyclosporine, and metformin. Do not use berberine as a replacement for prescribed treatment without consulting your physician. Always seek the advice of a qualified healthcare provider before starting any supplement regimen.

Few supplements have had a more dramatic cultural moment than berberine. Once confined to the shelves of specialty health stores and the protocols of integrative medicine practitioners, berberine has become something of a phenomenon — propelled partly by social media comparisons to semaglutide (sold as Ozempic and Wegovy), a prescription GLP-1 receptor agonist that has transformed the treatment of type 2 diabetes and obesity. The comparison has a surface-level appeal. Both compounds influence metabolic pathways involved in blood sugar regulation. Both are discussed in the context of weight management. Berberine is a fraction of the cost, available without a prescription, and marketed across wellness channels as a "natural" alternative. The shorthand — "nature's Ozempic" — spread quickly and widely. The problem is that shorthand compresses a complicated evidence picture into a slogan. What the randomized controlled trial (RCT) evidence on berberine actually shows is more interesting — and more nuanced — than either its most enthusiastic proponents or its dismissers tend to acknowledge.

13 May

Posted at 15:50h in Breast Cancer, Cancer Research, JAMA, Weight Research
MedicalResearch.com Interview with: [caption id="attachment_73639" align="alignleft" width="125"]Bernard F. Fuemmeler, PhD, MPHProfessor and Gordon D. Ginder, MD Chair in Cancer Research Associate Director of Population Science, Massey Comprehensive Cancer Center Director of Research, Family Medicine and Population Health Dr. Fuemmeler[/caption] Bernard F. Fuemmeler, PhD, MPH Professor and Gordon D. Ginder, MD Chair in Cancer Research Associate Director of Population Science, Massey Comprehensive Cancer Center Director of Research, Family Medicine and Population Health [caption id="attachment_73640" align="alignleft" width="125"]Kristina L. Tatum, PsyD, MSInstructor Department of Social and Behavioral Sciences School of Public Health Dr. Tatum[/caption] Kristina L. Tatum, PsyD, MS Instructor Department of Social and Behavioral Sciences School of Public Health A large population-based analysis of more than 841,000 breast cancer patients across the United States examines whether GLP-1 receptor agonist use is associated with improved survival and lower recurrence risk — with findings that researchers describe as very promising.
MedicalResearch.com: What is the background for this study? What are the main findings? Response: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used since 2005 and as the GLP1RAs treatments and delivery methods have improved, their use has markedly increased. Now it is estimated that nearly 1 in 8 US adults report ever using a GLP-1RA, which includes many people who are using them to treat obesity, diabetes, heart disease, and sleep apnea. There has been some preclinical data from mouse models to suggest that maybe GLP1RAs have an anticancer effect reducing the effects of obesity on tumor growth or progression. We were interested to understand to what extent GLP1RA use among cancer patients might be associated with cancer outcomes, like length of survival after cancer treatment or the chance of recurrence. In our large population-based study using an aggregate of de-identified electronic health record data from more than 841,000 patients with breast cancer across the US, we found that GLP-1 RAs use was associated with significantly improved survival and lower recurrence risk among patients with obesity or type 2 diabetes. Among patients with obesity, GLP-1 RAs use was associated with approximately 65% lower risk of death and a 56% lower risk of recurrence over 10 years compared with nonuse. We also observed substantially improved outcomes among patients with type 2 diabetes compared with insulin or metformin.

11 May

Posted at 11:28h in Weight Research
weight-loss-with-new-oral-medications.png

Key Takeaways

     
  • GLP-1 medications have revolutionized weight loss treatment, offering both injectable and oral options.
  • Recent FDA approvals have expanded access to these medications, with new oral formulations now available.
  • While effective, GLP-1 medications can have side effects, emphasizing the need for medical supervision.
  • Incorporating dietary fiber can help mitigate some gastrointestinal side effects associated with GLP-1 medications.
 

Table of Contents

  1. Introduction
  2. Understanding GLP-1 Medications
  3. Recent FDA Approvals
  4. Potential Side Effects
  5. Dietary Considerations
  6. Importance of Medical Supervision
  7. Conclusion
 

Introduction

In recent years, the field of weight management has experienced significant changes, thanks to a class of drugs called GLP-1 receptor agonists. These medications, which started as treatments for type 2 diabetes, have demonstrated remarkable success in supporting weight loss. Their widespread acceptance and endorsements by healthcare providers stem from their ability to help users not only lose weight but also maintain healthier lifestyles over the long term. Individuals seeking up-to-date and reputable information on options like Semaglutide for Weight Loss can explore how these solutions have changed the landscape of obesity treatment. In recent years, the field of weight management has experienced significant changes, thanks to a class of drugs called GLP-1 receptor agonists. These medications, which started as treatments for type 2 diabetes, have demonstrated remarkable success in supporting weight loss. Their widespread acceptance and endorsements by healthcare providers stem from their ability to help users not only lose weight but also maintain healthier lifestyles over the long term. GLP-1 medications are reshaping how both doctors and patients approach chronic weight issues. Unlike older interventions, these medications address appetite regulation at a hormonal level. With the introduction of oral alternatives, more people can now benefit from these scientifically backed therapies.

08 Oct

Posted at 15:28h in Author Interviews, Weight Research

GLP-1 Medications For Weight Loss: Benefits and Potential Side Effects

[caption id="attachment_70925" align="aligncenter" width="500"]weight-loss-drugs-semaglutide Photo by Suzy Hazelwood[/caption] By Palvinder Deol, Superintendent Pharmacist, Happy Pharmacy Obesity is a complex, multifactorial disease that continues to pose one of the greatest public health challenges of our time. According to the World Health Organization, global obesity rates have nearly tripled since 1975, with more than one billion adults now classified as overweight or obese. Despite growing awareness of the health risks associated with excess weight — including cardiovascular disease, type 2 diabetes, and certain cancers — achieving and sustaining weight loss remains difficult for many individuals. Over the past few years, advances in pharmacological science have transformed the landscape of obesity management. Treatments targeting hormonal pathways, particularly GLP-1 receptor agonists, have shown remarkable efficacy in supporting meaningful, long-term weight reduction when combined with healthy lifestyle changes.

30 Jun

Posted at 13:27h in Weight Research
Potential Risks of Using Ozempic and Rybelsus Ozempic and Rybelsus are medications that have become increasingly popular for managing type 2 diabetes and, more recently, for off-label use in weight loss. Both drugs contain semaglutide, a compound that mimics a hormone that is involved in the regulation of blood sugar and control of appetite. These drugs do work for many patients, but they are not without risk. With their use increasing, concern has grown over potential side effects. As more patients turn to these medications, it's essential to weigh the benefits against the risks. Understanding how each drug affects the body can help make safer choices. That’s why an Ozempic vs Rybelsus safety comparison is key for anyone considering these treatments.

1.   Gastrointestinal Issues

One of the most common side effects patients report experiencing with Ozempic and Rybelsus is gastrointestinal discomfort. Patients often report nausea, vomiting, diarrhea, and abdominal pain, especially when treatment is initiated or the dose is adjusted. These symptoms can be mild and last a few weeks. Such discomfort is sometimes severe enough to result in dehydration or discontinuation of therapy. This can exacerbate symptoms in individuals who already have other pre-existing digestive problems.

22 Apr

Posted at 11:40h in Author Interviews
Editor's note: Please remember you need a valid prescription to purchase Ozempic in the US or online. Online semaglutide purchases may not be FDA approved and may carry some additional risks.  Purchases online of Ozempic or products are not warranted or guaranteed by MedicalResearch.com. [caption id="attachment_68088" align="aligncenter" width="500"]weight-loss-semaglutide Source[/caption] With weight loss medications taking center stage in health discussions, Ozempic has become a household name. While originally developed to treat and control type 2 diabetes, it has gained global attention for its potential role in weight loss. For individuals exploring new avenues to support their health goals, getting Ozempic border free emerges as a convenient way to access the medication. In this article, we'll break down how Ozempic works, its effectiveness for weight loss, possible side effects, and what you should consider before starting it. Whether you're dealing with weight-related health issues or simply exploring safe, medical fat loss aids, this guide will help clarify your options.

31 Oct

Posted at 11:33h in Author Interviews, Diabetes, Kidney Disease, Nature, Semaglutide
MedicalResearch.com Interview on publication of: [caption id="attachment_64443" align="alignleft" width="200"]Prof. dr. H.J. (Hiddo) Lambers HeerspinkClinical Pharmacologist Faculty of Medical Sciences University of Groningen Prof. Heerspink[/caption] Prof. dr. H.J. (Hiddo) Lambers Heerspink Clinical Pharmacologist Faculty of Medical Sciences University of Groningen MedicalResearch.com: What is the background for this study? What are the main findings? Response: The diabetes drug semaglutide, also known as Ozempic, has a positive effect for patients with chronic kidney damage and obesity. The amount of protein in their urine decreased, as did the degree of inflammation of their kidneys and their blood pressure. Hiddo L. Heerspink got the idea for this study at the beginning of the corona pandemic. Earlier, he had discovered that another class of drugs against diabetes-2, the so-called SGLT2 inhibitors also appeared to work well for patients with chronic kidney damage without diabetes. He therefore wanted to investigate whether semaglutide would also work positively for patients with chronic kidney disease and obesity.

19 Oct

Posted at 10:02h in Semaglutide, Weight Research
[caption id="attachment_64111" align="aligncenter" width="500"]weight-loss-drugs Source[/caption] In recent years, injectable weight loss medications have surged in popularity, becoming a preferred choice for individuals seeking effective and sustainable weight management solutions. This trend is driven by advancements in medical science, increased awareness of obesity-related health risks, and the convenience offered by online healthcare platforms. Among the various options available, medications like semaglutide and tirzepatide have gained significant attention for their efficacy in promoting weight loss.

Understanding Injectable Weight Loss Medications

Injectable weight loss medications are typically prescribed for individuals struggling with obesity or those who have not achieved desired weight loss results through diet and exercise alone. These medications work by targeting specific hormones and receptors in the body that regulate appetite, metabolism, and fat storage. Unlike oral weight loss pills, injectables often provide more consistent and potent effects, making them a viable option for long-term weight management.

23 Sep

Posted at 20:08h in Semaglutide, Weight Research
Ozempic (semaglutide) is a prescription medication designed to help manage type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists, which work by increasing insulin production, reducing blood sugar levels, and slowing digestion to help improve glucose control. Ozempic has also gained attention for its potential role in weight management, but its primary use is for patients with type 2 diabetes who need help controlling their blood sugar. To get the best results from Ozempic, following the correct dosing schedule is critical. A structured approach to dosage allows the body to adjust to the medication, reduces the likelihood of side effects, and ensures that patients achieve optimal blood glucose control over time. Many people also explore options to buy Ozempic from Canada as a way to save on costs while maintaining their treatment regimen In this article, you will learn about Ozempic dosing, how to follow the dosing schedule, where to inject, what to do if you miss a dose, and more. Read on to find out how you can also save on Ozempic when you order through BuyCanadianInsulin.com. Editor' note: If you are purchasing Ozempic from Canada, please ensure it is legal where you live and that you are not purchasing a counterfeit product.

18 Sep

Posted at 13:04h in Semaglutide, Weight Research
If you’ve been hearing a lot of buzz about the Wegovy pen and are curious about what it can do for weight loss, you're in the right place. There’s a lot to understand, but we’re going to break it down into simple, easy-to-follow information. Whether you're exploring your options or have already made up your mind about giving it a try, here's everything you need to know about the Wegovy pen. [caption id="attachment_63382" align="aligncenter" width="500"]semaglutide-weight-loss_pexels-pixabay-53404 Source[/caption]

What is the Wegovy Pen?

Let’s start with the basics. The Wegovy pen is a once-weekly injectable medication that’s used to support weight loss in adults. It contains the active ingredient semaglutide, which is designed to help regulate appetite. In simple terms, it helps you feel fuller for longer, so you're less likely to overeat. Semaglutide mimics a hormone called GLP-1 (glucagon-like peptide-1), which plays a role in controlling hunger. By imitating this hormone, Wegovy helps reduce food cravings and manages how much you eat.

17 Sep

Posted at 17:24h in Author Interviews
Editor's note: If you purchase semaglutide or similar medications, be sure to be followed by your health care provider and verify that the supplier is reputable before your purchases. When it comes to weight loss, it often feels like everyone has an opinion. Some swear by keto, while others say it's all about intermittent fasting. And let’s not forget the ever-popular crash diets that promise instant results but leave you feeling sluggish and starving. With so much conflicting advice, how can you figure out what actually works? This post attempts to break down the science behind weight loss, cutting through the noise and getting to the core of what really makes a difference in shedding those extra pounds—without the fads. weight-obesity-scale

Calories In, Calories Out: The Basics

At its most fundamental level, weight loss comes down to one basic principle: calories in versus calories out. The idea is simple—if you consume fewer calories than your body needs, you'll lose weight. This is known as creating a calorie deficit. Your body has to find energy somewhere, and when you're not giving it enough through food, it starts to use stored fat. However, it's not always as straightforward as it seems. People have different metabolic rates, meaning some burn calories faster than others. Plus, hormones, genetics, and lifestyle factors can all affect how easy or difficult it is to drop pounds. This is why two people on the same diet might experience different results. Key takeaway: To lose weight, you need to consistently eat fewer calories than you burn. But keep in mind that individual factors can influence how quickly (or slowly) this happens for you.

04 Sep

Posted at 22:18h in Nutrition, Weight Research
Semaglutide has emerged as a promising medication for weight loss, offering significant results for many users. Wegovy's semaglutide , a glucagon-like peptide-1 (GLP-1) receptor agonist, works by mimicking a natural hormone that regulates appetite and food intake. Combining semaglutide with healthy lifestyle changes can accelerate weight loss and improve overall outcomes. [caption id="attachment_63140" align="aligncenter" width="500"]semaglutide-weight-loss_pexels-gustavo-fring-5622219 Source [/caption] While semaglutide alone can lead to impressive weight reduction, there are strategies to enhance its effectiveness. Eating a nutritious, low-calorie diet rich in fiber and protein can complement the appetite-suppressing effects of the medication. Regular physical activity further supports weight loss efforts and overall health improvements. It's important to note that the full effects of semaglutide may take several weeks to become noticeable. Patience and consistency are key when using this medication for weight management. As with any weight loss journey, individual results may vary, but many users experience significant reductions in body weight over time.

Key Takeaways

  • Semaglutide mimics GLP-1 to regulate appetite and food intake
  • Combining the medication with a healthy diet and exercise enhances weight loss
  • Consistency and patience are crucial for optimal results with semaglutide

11 Aug

Posted at 16:31h in Pharmacology, Semaglutide
[caption id="attachment_62820" align="alignleft" width="200"]pharmacy-pills_pexels-artempodrez-4492065 Image Source[/caption] Oral Semaglutide has emerged as a significant advancement in the realm of weight loss treatments. As an alternative to traditional injectable options, oral Semaglutide offers convenience and effectiveness. This guide provides an in-depth look at oral Semaglutide, its benefits, how to access it through prescriptions, and explores compounded semaglutide online.

What is Oral Semaglutide?

Oral Semaglutide is an oral form of the medication Semaglutide, which was originally available only as an injection. It is used to manage weight loss and control blood sugar levels in individuals with obesity or type 2 diabetes.
  • Mechanism of Action: Semaglutide mimics a hormone called GLP-1, which helps regulate appetite and insulin secretion. By enhancing these processes, it can support significant weight loss and better blood sugar control.
  • Approval and Usage: The oral version is approved by the FDA for weight management and is typically prescribed as part of a comprehensive weight loss plan that includes diet and exercise.

10 Jun

Posted at 19:11h in Weight Research
Key Takeaways
  • Personalized weight management is crucial in achieving sustainable results.
  • Combined data from multiple sources enhances personalization.
  • Maintaining a relationship between providers and consumers boosts success rates.
The Need for Personalization in Weight Management Personalized weight management plans are essential in today's health-focused world, and research consistently shows their effectiveness over generic approaches. According to a study by the Centers for Disease Control and Prevention (CDC), customized weight management strategies lead to tremendous long-term success in weight loss. Additionally, platforms like BuildMyBod offer providers a turnkey solution to offer diverse services that cater to personal health needs, showing how personalization is becoming a cornerstone in weight management.

14 Feb

Posted at 16:46h in Author Interviews, Diabetes, Orthopedics, Weight Research
MedicalResearch.com Interview with: [caption id="attachment_61333" align="alignleft" width="150"]Matthew Magruder, MD PGY3Orthopaedic Residency Program Department of Orthopaedic Surgery and Rehabilitation Maimonides Medical Center Dr. Magruder[/caption] Matthew Magruder, MD PGY3 Orthopaedic Residency Program Department of Orthopaedic Surgery and Rehabilitation Maimonides Medical Center MedicalResearch.com: What is the background for this study? Response: The prevalence of obesity and diabetes mellitus has reached epidemic proportions. Approximately 37.3 million people in the United States, accounting for 11.3% of the total population, have diabetes, and 100.1 million, or 41.9%, of all US citizens are obese. Furthermore, these numbers are only projected to increase in the coming decades. This is an issue for orthopaedic surgeons because diabetes and obesity have consistently been demonstrated to be risk factors for complications following total joint replacements, especially total hip replacements. Therefore, we are in desperate need of new and more effective tools in mitigating the risk of poor outcomes in our joint replacement patients. Semaglutide, and other GLP-1 agonists, are potentially a new tool that can be used to help decrease the risks following joint replacement surgery. Initially a medication to treat diabetes, semaglutide has recently been approved by the FDA to treat obesity as well, as randomized controlled trials have consistently demonstrated significant weight loss with minimal side effects. The purpose of our study was to see what effect the use of semaglutide had on total hip arthroplasty patient outcomes.

25 Sep

Posted at 07:17h in Alcohol, Author Interviews
MedicalResearch.com Interview with: [caption id="attachment_60871" align="alignleft" width="150"]Prof. Elisabet Jerlhag HolmDepartment of Pharmacology Institute of Neuroscience and Physiology The University of Gothenburg Prof. Jerlhag Holm[/caption] Prof. Elisabet Jerlhag Holm Department of Pharmacology Institute of Neuroscience and Physiology The University of Gothenburg MedicalResearch.com: What is the background for this study? Response: Alcohol use disorder (AUD) is a conditioned associated with morbidity, mortality and costs for society. There are today 4 approved medications, but given the heterogeneity of the disease the efficacy of these is limited and new medications are needed. Peptides of the gut-brain axis, such as GLP-1, have been implied as novel treatment targets. We therefore investigated the effect of an agonist for GLP-1, semaglutide, on alcohol drinking in rodents.

28 Aug

Posted at 16:24h in Author Interviews, Dermatology, Diabetes, Heart Disease, Weight Research
MedicalResearch.com Interview with: [caption id="attachment_60815" align="alignleft" width="150"]Dr. Alexis Elias MalavazosEndocrinology Unit Clinical Nutrition and Cardiovascular Prevention Service, IRCCS Policlinico Unit of Radiology, IRCCS Policlinico San Donato, San Donato Milanese, Italy Dr. Malavazos[/caption] Dr. Alexis Elias Malavazos Endocrinology Unit Clinical Nutrition and Cardiovascular Prevention Service, IRCCS Policlinico Unit of Radiology, IRCCS Policlinico San Donato, San Donato Milanese, Italy   MedicalResearch.com: What is the background for this study? Response: Psoriasis is a systemic inflammatory disease often associated with obesity and type-2 diabetes (T2D). The inflammatory process of psoriasis can target adipose tissue depots, particularly those surrounding the heart and the coronary arteries, exposing them to an increased risk of cardiovascular disease.

16 May

Posted at 11:47h in Author Interviews, Diabetes, Gastrointestinal Disease, Weight Research
MedicalResearch.com Interview with: [caption id="attachment_57425" align="alignleft" width="200"]Dr. Hoff Dr. Hoff[/caption] Anna Carolina Hoff, MD Lead researcher on the study Founder and Clinical Director Angioskope Brazil São José dos Campos  MedicalResearch.com: What is the background for this study? Response: Obesity is a chronic disease that has become a global pandemic, and its prevalence continues to increase. Overweight (Body Mass Index (BMI) ≥ 27 kg/m2) and obesity (BMI ≥ 30kg/m2) lead to numerous clinical comorbidities, including metabolic, cardiovascular, oncologic, and mental health disorders. It is challenging to achieve significant and sustained weight loss with diet and lifestyle modification alone. Additionally, a reversal of obesity-related co-morbidities and improvement in quality of life entails a percent total body weight loss (%TBWL) of between 5-10%, which is rarely achieved with medications alone. The Endoscopic Sleeve Gastroplasty (ESG) results in a %TBWL between 14.6%-19.7% at 18-24 months,  and improvements in systolic blood pressure (SBP), HbA1c, and dyslipidemia at 12 months.